7th POSTGRADUATE SYMPOSIUM
|
|
|
- Cody McDonald
- 10 years ago
- Views:
Transcription
1 Institute of Pathology In cooperation with:»» Leibniz Institute for Age Research (Fritz Lipmann Institute) IZKF Graduate Program for Experimental Medicine»» Leibniz Institute for Natural Products and Infection Biology Jena (Hans-Knöll-Institute) 7th POSTGRADUATE SYMPOSIUM ON CANCER RESEARCH Saturday, April 25, 2015 Altes Schloss Dornburg (Kaisersaal) 1
2 ORGANIZATION Institute of Pathology, Jena University in collaboration with» Interdisciplinary Center for Clinical Research (IZKF) Graduate Program for Experimental Medicine, University Jena» UniversitätsTumorCentrum (UTC) Jena» Leibniz Institute for Age Research (Fritz Lipmann Institute)» Leibniz Institute for Natural Products and Infection Biology Jena (Hans-Knöll-Institute)» Jena School of Molecular Medicine» Jena Graduate Academy Prof. Dr. Iver Petersen, Prof. Dr. Alexander Berndt Phone: +49-(3641) SCIENTIFIC COMMITEE Backsch, Claudia Häfner, Norman Baniahmad, Aria Heller, Regine Beck, James Friderich Hilger, Ingrid Berndt, Alexander Hochhaus, Andreas Berndt, Angela Huber, Otmar Böhmer, Frank-Dietmar Liehr, Thomas Chen, Yuan Markert, Udo Clement, Joachim H. Melle, Christian Dürst, Matthias Petersen, Iver Englert, Christoph Popp, Jürgen Ewald, Christian Schulz, Stefan Franz, Marcus Stallmach, Andreas Friedrich, Karlheinz Wang, Zhao-Qi Guntinas-Lichius, Orlando Weigand, Wolfgang Hansel, Alfred 2
3 LOCATION Kaisersaal, Altes Schloss Dornburg TRAVELLING By train: Take the regional train from Jena-Paradies to Dornburg (Saale). See following link to check the schedule: By car (from Jena): Caution: the street lead to Altes Schloss Dornburg is now under construction. Please take the alternate detour route. Give (Jena to: , to: , to:dornburg/saale) to your navigation or Google Map (Schloßplatz, Camburg, Germany) Das Symposium ist als ärztliche Fortbildungsveranstaltung im Rahmen des Fortbildungszertifikats der Landesärztekammer Thüringen anerkannt (Kategorie A, Punkte 9). 3
4 THIS SYMPOSIUM IS SUPPORTED BY: Boehringer Ingelheim Pharma GmbH & Co. KG....(with 500 ) Carl Zeiss Jena GmbH...(with 750 ) Dako Deutschland GmbH...(with 500 ) Lilly Deutschland GmbH...(with 750 ) Merck Serono GmbH...(with 500 ) Novartis Pharma GmbH...(with 1250 ) QIAGEN GmbH... (with symposium materials) Roche Pharma AG...(with 1000 ) Zytomed systems GmbH....(with 500 ) ZytoVision GmbH....(with 500 ) 4
5 PROGRAM 8:00 Registration 9:00 Welcome address Prof. Dr. O. Guntinas-Lichius, Vice Dean of Study Affairs of the Medical Faculty of the Friedrich Schiller University of Jena 9:10 JIP Cancer Graduation Award Introduction Prof. Dr. Andreas Hochhaus, Director of the Department for Internal Medicine II, Jena University ; Vice-dean for Research of Medical Faculty of FSU; Director of the UniversitätsTumorCentrum Jena Lecture of the laureate 9:30 Keynote lecture Prof. W.W. Franke (Helmholtz Group for Cell Biology, German Cancer Research Center DKFZ): Molecular Diagnostics: Immunocytochemistry using cytoskeletal and junctional cell type markers 10:30 Coffee break 11:00 ORAL PRESENTATIONS SESSION 1: TUMOR CELL BIOLOGY Chairs: Frank Böhmer, Daniel Kritsch 1 Inhibitor of Growth 2 Inhibits Androgen Receptor Signaling in Prostate Cancer Cells Pungsrinont, Thanakorn; Institute of Human Genetics, Jena University 2 Androgen-dependent regulation of long non-coding RNAs in prostate cancer Maiwald, Caroline; Institute of Human Genetics, Jena University 3 Androgen receptor-dependent regulation of htert Kacal, Merve; Institute of Human Genetics, Jena University 5
6 4 AR-dependent regulation of genes involved in epithelial-mesenchymal transition in prostate cancer cells Colditz, Juliane; Institute of Human Genetics, Jena University 5 Protein tyrosine phosphatase expression analysis in chronic myeloid leukemia (CML)- patient samples and cell lines Drube, Julia; Institute of Molecular Biology, Jena University 6 Bidirectional HGF/c-Met signalling in the bladder cancer microenvironment Jennek, Susanne; Institute of Biochemistry II, Jena University 7 A ChIP-Seq and microarray based approach identifies Wt1 target gene Dong, Lihua; Molecular Genetics, Leibniz Institute for Age Research- Fritz Lipmann Institute (FLI) 8 MCPH1 acts as a modulator of βtrcp2 to regulate mitotic entry Liu, Xiaoqian; Leibniz Institute for Age Research - Fritz Lipmann Institute (FLI) 13:00 Lunch Snack 13:45 POSTER SESSION 1: TUMOR CELL BIOLOGY Chairs: Regine Heller, Joachim Clement 9 The DNA damage independent function of NBS1 in brain development Wang, Pei; Leibniz Institute for Age Research - Fritz Lipmann Institute (FLI) 10 DNA double-strand break induces colocalization between 53BP1 and S100A11 Bayer, Cathrin; Working group Biomolecular Photonics, Jena University 11 BIRC3 aberrations in chronic and B-cell acute lymphocytic leukemia patients Alhourani, Eyad; Institute of Human Genetics, Jena University 6
7 12 Relevance of ITIH5 for cervical carcinogenesis Dittmann, Jessica; Department of Gynecology, Jena University 13 MLL gene displaying an important molecular biomarker in acute leukaemia Othman, Moneeb A.K.; Institute of Human Genetics, Jena University 14 Detection of cervical carcinoma specific biomarkers by digital PCR Carow, Katrin; Department of Gynecology, Jena University 15 Abnormal expression of keratin 19 in lung carcinoma cell lines Wölfel, Cornelius; Institute of Pathology, Jena University 16 The role of SKAP in mitosis Vranesic, Anita Cindric; Institute of Biochemistry II, Jena University 17 Desmocollin 3 acts as a tumor suppressor through inhibiting PI3K/AKT/ MDM2 signaling in human colorectal cancer Ma, Yunxia; Institute of Pathology, Jena University POSTER SESSION 2: TUMOR DIAGNOSTIC AND THERAPY Chairs: Karlheinz Friedrich, Marcus Franz 18 Synthesis and biological behavior of O,S-chelating platinum(ii) and ruthenium(ii) complexes Hildebrandt, Jana; Institute of Inorganic and Analytical Chemistry, Jena University 19 FAS-Expression and survival as possible predictors in Human Glioblastoma? Vestergaard, Anita-Maria; AG Experimentelle Neuroonkologie, Klinik für Neurochirurgie, Jena University 7
8 20 EGCG induces cell death in human glioblastoma cell cultures Kögler, Christine; AG Experimentelle Neuroonkologie, Klinik für Neurochirurgie, Jena University 21 Novel cryptic rearrangements in adult B-cell precursor acute lymphoplastic leukemia involving MLL-gene Rittscher, Katharina; Institute of Human Genetics, Jena University 22 Tumour comorbidities in polycystic kidney disease Joorabchi, Samrand; Institute of Pathology, Jena University 23 Role of protein tyrosine phosphatases in the development of antiangiogenic therapy resistance in renal cell carcinoma Weiland, Anne; Institute for Molecular Cell Biology, Centre for Molecular Biomedicine (CMB), Jena University 24 Activated gamma/delta (γδ) T cell subsets after Salmonella stimulation Polasky, Christina; Institute of Molecular Pathogenesis, Friedrich- Loeffler-Institut (FLI) 25 Effect of the autophagy inhibitor chloroquine on gefitinib-resistant lung cancer cells and clinical relevance of autophagy-associated proteins Schnitzler, Kai-Leonie; Institute of Pathology, Jena University 26 Does epithelial to mesenchymal transition influence ALA accumulation in bladder cancer cells? Schleier, Richard; Institute of Pathology, Jena University 27 Heterogeneous response in cellular survival to MTX-MNP and hyperthermia exposure Pömpner, Nadine; Institute of Diagnostic and Interventional Radiology, Jena University 8
9 POSTER SESSION 3: TUMOR MICROENVIRONMENT AND EPIGENETIC REGULATION Chairs: Yuan Chen, Thomas Liehr 28 Serum-depletion affects protein trophoblast expression, resembling a tumoral adaptive switch Novoa-Herran, S; Placenta-Labor, Department of Obstetrics, Jena University 29 Methylation of specific genes in the course of cervical carcinogenesis: correlation to gene expression Eiselt, Juliane; Department of Gynecology, Jena University 30 Characterization of genes related to cisplatin-resistance in ovarian carcinoma cell lines Kritsch, Daniel; Department of Gynecology, Jena University 31 Influence of soy phytoestrogens on the uterine gene expression in mice Favaro, Rodolfo R; Placenta-Labor, Department of Obstetrics, Jena University 32 Coated superparamagnetic nickel nanorods affect cell vitality and intracellular signalling Schmidt, Ann-Kathrin; Abt. Hämatologie und Internistische Onkologie, Jena University 33 Raman spectroscopical investigations of senescence in human primary fibroblast cells Eberhardt, Katharina; Leibniz Institute of Photonic Technology (IPHT) Jena 34 Proteasomal decline in endothelial senescence Meçe, Odeta; Institute for Molecular Cell Biology, Centre for Molecular Biomedicine (CMB), Jena University 9
10 35 Angiogenesis is dependent on endothelial autophagy the role of AMPK Spengler, Katrin; Institut for Molecular Biology, Centre for Molecular Biomedicine (CMB), Jena University 36 Sodium-hydrogen exchanger NHE1 in endothelial cells regulates angiogenesis Kryeziu, Nderim; Institute for Molecular Cell Biology, Centre for Molecular Biomedicine (CMB); Jena University 37 Multicellular spheroids: A model for nanoparticle-cell interaction studies Demut, Johanna; Abt. Hämatologie und Internistische Onkologie, Jena University 15:00 ORAL PRESENTATIONS SESSION 2: TUMOR DIAGNOSTIC AND THERAPY Chairs: Ferdinand von Eggeling, Susanne Jennek 38 Functional analysis of CAMK2N1 and RUNX3 in Ovarian Carcinogenesis Heinze, Karolin; Department of Gynecology, Jena University 39 Measuring G protein signaling with a fluorescence-based membrane potential assay Günther, Thomas; Department of Pharmacology and Toxicology, Jena University 40 MALDI-Imaging: Mapping the cancer Hoffmann, Franziska; ENT Department, Jena University 41 Classification and prediction of liver cancer by Raman imaging Tolstik, Tatiana; Department of Internal Medicine IV, Division of Gastroenterology, Hepatology and Infectious Diseases, Jena University 10
11 17:00 Break 42 The expression of the protein lysine demethylases KDM1A, KDM2B, KDM5B and KDM6B is associated with poor clinical outcome in childhood acute lymphoblastic leukaemia Walter, Elisabeth; Department of Paediatric Haematology and Oncology, Children s ; Jena University 43 Inhibition of Breast Cancer Proliferation by Androgen Receptor Antagonists Luko, Katarina; Institute of Human Genetics, Jena University 44 Molecular analysis of CETCs in patients with hepatocellular carcinoma Berger, Tina; Abt. Hämatologie und Internistische Onkologie, Jena University 45 Detection of fetal fibronectin variants in patients serum: Implications for individualized targeted tumor therapy using armed antibodies Ospel, Johanna; Department of Internal Medicine I, Jena University 17:30 Dinner / Awards 11
12 Institute of Pathology, Jena University Prof. Dr. Iver Petersen, Prof. Dr. Alexander Berndt Phone: +49-(3641)
Interdisciplinary Center for Clinical Research (IZKF), University Hospital Jena
1 ORGANIZATION Interdisciplinary Center for Clinical Research (IZKF), University Hospital Jena in collaboration with UniversitätsTumorCentrum (UTC) Jena Leibniz Institute for Age Research - Fritz Lipmann
Interdisciplinary Center for Clinical Research (IZKF), University Hospital Jena
ORGANIZATION Interdisciplinary Center for Clinical Research (IZKF), University Hospital in collaboration with UniversitätsTumorZentrum (UTC) Leibniz Institute for Age Research - Fritz Lipmann Institute
16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG
16 TH -17 TH 2015 NOVEMBER INNOVATIONS IN ONCOLOGY HEIDELBERG INNOVATIONS IN ONCOLOGY HEIDELBERG, NOVEMBER 16 TH - 17 TH 2015 German Cancer Research Center (DKFZ) Heidelberg - Germany Hosted by the National
Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy
Programme Invited Speakers: Reuven Agami (The Netherlands), Manuela Baccarini (Austria), Allan Balmain (USA), Daniel Birnbaum (France), Anne-Lise Børresen-Dale (Norway), Carlos Caldas (UK), Silvana Canevari
Future Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
Cell Culture Days 2015
Cell Culture Days 2015 Thursday, 07.05.2015 9:00 11:00 Tissue and 3D Cell Culture Giving cancer a shape: 3-dimensional in vitro and ex vivo lung carcinoma Katharina Leithner Organotypic cultures: Methods
American Cancer Society Extramural Grants
Page: 1 Institutional Research Grant (IRG) IRG-14-247-29 You, Ming, MD, PhD Department of Pharmacology and Toxicology Institutional Research Grant 01/01/2015 12/31/2016 $240,000 Summary IRG Total Number
Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen
Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical
Fulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
Future Directions in Cancer Research What does is mean for medical physicists and AAPM?
Future Directions in Cancer Research What does is mean for medical physicists and AAPM? John D. Hazle, Ph.D., FAAPM, FACR President-elect American Association of Physicists in Medicine Professor and Chairman
Cancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi
Cancer SBL101 James Gomes School of Biological Sciences Indian Institute of Technology Delhi All Figures in this Lecture are taken from 1. Molecular biology of the cell / Bruce Alberts et al., 5th ed.
TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
Department of BioScience Technology Chung Yuan Christian University 2015/08/13
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
Midwinter Conference 2015 January 17-22 Seefeld, Tyrol CONFERENCE PROGRAM. midwinter2015.org. Sponsored by
Midwinter Conference 2015 January 17-22 Seefeld, Tyrol CONFERENCE PROGRAM Sponsored by SATURDAY, 17 January 18.00-19.00 Keynote lecture Richard Flavell Sponsored by 19.00 Welcome Reception Hosted by SUNDAY,
Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008
33 rd European Symposium on Hormones and Cell Regulation Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers Mont Ste. Odile, Alsace, France 11-14 September 2008 Invited Speakers:
A Career in Pediatric Hematology-Oncology? Think About It...
A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T
QUANTITATIVE APPROACHES IN CELL BIOLOGY BIOPHYSICS, BIOENGINEERING & SYSTEMS BIOLOGY
QUANTITATIVE APPROACHES IN CELL BIOLOGY BIOPHYSICS, BIOENGINEERING & SYSTEMS BIOLOGY SignGene Symposium 2014 August 31 - September 2, 2014 Max Delbrück Center for Molecular Medicine Berlin, Germany www.mdc-berlin.de/signgenesymposium2014
treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens
Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.
From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes
ISSN 2154-4006 The Genetic Basis of Human Disease zbar Colloquium series on Series Editor: Michael Dean, Ph.D., Head, Human Genetics Section, Senior Investigator, Laboratory of Experimental Immunology
A disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
American Cancer Society Extramural Grants
Page: 1 Clinical Research Professorship (CRP) CRP-14-114-06 Eng, Charis, MD, PhD Cleveland Clinic Foundation Genomic Medicine Institute PTENopathies and Cancer Phenomics 07/01/2014 06/30/2019 $400,000
TEXT PICTURE. Martin Puhr PhD. Medical University of Innsbruck. Department of Urology Division of Experimental Urology
TEXT PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer PICTURE Martin Puhr PhD Department of Urology
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:
Biofocus Molecular Diagnostic Panel
Biofocus Molecular Diagnostic Panel Dr. Lothar Prix Biofocus GmbH, Recklinghausen, Germany www.biofocus.de Molecular detection of infectious diseases Human & veterinary hereditary diseases / genetic predisposition
NOVEL PLATFORMS FOR CANCER DIAGNOSIS
NOVEL PLATFORMS FOR CANCER DIAGNOSIS Luca Beneduce, Ph.D. Founded in 2001 and headquartered in Venice (Italy) Xeptagen is a privately held biotech company funded by venture capital. Xeptagen s mission
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Fragment-based lead generation of reversible inhibitors for lysine-specific demethylases
Fragment-based lead generation of reversible inhibitors for lysine-specific demethylases www.beactica.com Ulf Bremberg CSO Beactica AB Drug Discovery 2015 Elrig 3 Sept 2015 Presentation overview Beactica
What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
Cellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
MDC CareerDay April 16, 2015 PROGRAM
FOYER, MDC.C 8:30 9:00 REGISTRATION 9:00 9:15 OPENING AND WELCOME Prof. Dr. Gary Lewin Chairman of the Scientific Council, Max Delbrück Center for Molecular Medicine (MDC) 1 9:15 10:00 KEYNOTE TALK I:
2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber
Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it
Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it The University of Udine is an Italian Public University founded in 1978 by National Law No. August 8, 1977 546, art.
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science
CURRICULUM FOR RESEARCH POSTGRADUATE PROGRAMS Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science Curriculum for Master of Philosophy (MPhil) Program in Life Science The
Investigating Community Cancer Concerns--Deer Park Community Advisory Council, 2008
Investigating Community Cancer Concerns--Deer Park Community Advisory Council, 2008 David R. Risser, M.P.H., Ph.D. [email protected] Epidemiologist Cancer Epidemiology and Surveillance Branch
FACULTY OF ALLIED HEALTH SCIENCES
FACULTY OF ALLIED HEALTH SCIENCES 102 Naresuan University FACULTY OF ALLIED HEALTH SCIENCES has focused on providing strong professional programs, including Medical established as one of the leading institutes
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
Cancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
New strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February
Notch 1 -dependent regulation of cell fate in colorectal cancer
Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1
Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
Foundations of Oncology Nursing Practice
Foundations of Oncology Nursing Practice Course Syllabus Course Lead:, RN, MN, BScN, CON(C) Associate Faculty:, RN, CON(C) Last updated January 27, 2011 Course Description: This online course will introduce
Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
Wadsworth Center. New York State Department of Health. The New Faces BMS
New York State Department of Health The New Faces of BMS The New Faces of BMS Jason Wong Adriana DePesters Jason is enrolled in the PhD course for the Fall session in the Department of Biomedical Science.
Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer
Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis
The Postgraduate Course Toxicology Vienna
The Postgraduate Course Toxicology Vienna Completion as Master of Science (Toxicology) Beginning of next course: Summer term 2016 OPEN FOR REGISTRATION AT ANY TIME Contents: History Objectives Participants
International Conference of the Korean Society for Molecular and Cellular Biology
International Conference of the Korean Society for Molecular and Cellular Biology Oct. 21 (Tue) ~ 23 (Thu), 2014 Korean Society for Molecular and Cellular Biology www.visitkorea.or.kr www.ksmcb.or.kr October
Targeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS -
Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS - January 2005 SCIENTIFIC BACKGROUND Breast cancer is considered to be one of the most prevalent cancer in women. The overall
Types of Cancers [-oma growth ]!
Cancer: disease of transcription factors and replication 1 Uncontrolled cell growth and division -> immortalized cells -> tumor growth -> metastasis (cells float away from tumor and spread throughout the
Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy
Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center Michael Atkins, MD Consulting Fees (e.g., advisory
Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1
9/8/2015 Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 Stefan Eichmüller, PhD GMP & T Cell Therapy Unit, German Cancer Research Center, Heidelberg, Germany
Big Data in Medicine
Symposium Big Data in Medicine Joint Symposium of the German National Academy of Sciences Leopoldina and the Hasso Plattner Institute for Software Systems Engineering July 1-2, 2015 Hasso Plattner Institute
Developments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD [email protected] Contents Introduction Lung cancer pathogenesis NSCLC treatment options
Leukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases M. Trauner, Division of Gastroenterology and Hepatology, Department of Internal Medicine, MUG Co- Investigator: H. Samonigg,
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic
FASEB Directory of Members Online
Head, Department of Anatomy and Radiology The College of Veterinary Medicine at the University of Georgia invites nominations and applications for the position of Head of the Department of Anatomy and
Targeted Therapeutics Propelling Discovery through Genomic Data
Two Innovative Events for Accelerating Science and Data Interpretations into Effective Treatments November 5-6, 2015 Hilton San Francisco Union Square Hotel San Francisco, CA Propelling Discovery through
Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases
The International School of Advanced Molecular BioMedicine Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases AciTrezza (Catania), Italy, October 2nd-6th, 2009 Hieronymus Bosch: Garden
Course Curriculum for Master Degree in Medical Laboratory Sciences/Hematology and Blood Banking
Course Curriculum for Master Degree in Medical Laboratory Sciences/Hematology and Blood Banking The Master Degree in Medical Laboratory Sciences /Hematology & Blood Banking, is awarded by the Faculty of
Biostatistics Credit 15 5 10 1. Integrated and Interdisciplinary Training 2/7 Credit 24 24 1
1st Year Hours SEMESTER I Exam or credit Total Lecture Seminar Classes ECTS Anatomy 1/2* Credit 100 20 80 9 Biophysics Exam 55 15 10 30 4 First Aid in Emergency Situations Credit 20 6 4 10 1 Histology
Cancerfondens planeringsgrupp för Onkologisk Nuklidterapi meeting 2015 25-27 November 2015
Cancerfondens planeringsgrupp för Onkologisk Nuklidterapi meeting 2015 25-27 November 2015 Place: Lecture Hall EKEN, Entrance 65, CAMPUS US, The Faculty of Medicine and Health Science, Linköping University,
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
1. Program Title Master of Science Program in Biochemistry (International Program)
1 Program Structure and Specification Master of Science Program in Biochemistry (International Program) Curriculum Last Revised in 2012 for Students Entering in Academic Year 2016 -----------------------------------------
Wissenschaftliche Highlights der GSF 2007
H Forschungszentrum für Umwelt und Gesundheit GmbH in der Helmholtzgemeinschaft Wissenschaftlich-Technische Abteilung Wissenschaftliche Highlights der GSF 2007 Abfrage April 2007 Institut / Selbst. Abteilung
Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1)
Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1) Verónica Cánovas, PhD Student Laboratory of Cell Signalling and Cancer Progression, Dra. Rosanna Paciucci
INTERNATIONAL COURSE:
INTERNATIONAL COURSE: Novel mechanisms of signal transduction involved in cancer chemoresistance - Focus on IGF signaling integration and cross-talk. University Campus S Venuta - Catanzaro, Italy Lecture
INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance
A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific
THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.
Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
How To Learn More About Melanoma
PROGRAMMA SCIENTIFICO MELANOMA BRIDGE 2012, DECEMBER 2 ND -4 TH 2012 Presidents: Paolo A. Ascierto, Francesco M. Marincola and Nicola Mozzillo Scientific Board Paolo A. Ascierto Gennaro Ciliberto Bernard
FINAL AND PERMANENT VERSION THURSDAY, FEBRUARY 17, 2011 DAY 1 (FRIDAY, MAY 6, 2011): Chairpersons: E. Özer (TR) - S.A.Raptis (GR)
FINAL AND PERMANENT VERSION THURSDAY, FEBRUARY 17, 2011 1 st TURKISH-HELLENIC POSTGRADUATE CONTINUOUS MEDICAL EDUCATION MEETING MAY 6-9, 2011, IZMIR, TURKEY DAY 1 (FRIDAY, MAY 6, 2011): Chairpersons: E.
Master BioMedical Sciences (BMS) Track Cell Biology and Advanced Microscopy
Master BioMedical Sciences (BMS) Track Cell Biology and Advanced Microscopy The five tracks offered in the Medical Biology cluster are: Biochemistry and Metabolic Diseases Cell Biology and Advanced Microscopy
One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3
1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
DFG. DFG Hinterzartener Kreis für Krebsforschung. From Molecular Mechanisms to Cancer Therapy
DFG Hinterzartener Kreis für Krebsforschung From Molecular Mechanisms to Cancer Therapy April 23rd-26th, 2015 Villa La Collina Cadenabbia (Co), Italy Program Committee Anja Bosserhoff, Erlangen (Chair)
